SEC Form 4 · accession 0000886163-17-000138
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
Nov 16, 2017
Accepted (ET)
Nov 17, 2017 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 16, 2017 | S | 5,000 | $141.71 | D | 35,649 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person contributed LGND common stock to an exchange fund in exchange for shares of the exchange fund. The LGND common stock was valued at $141.71 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person.